Research & Literature

Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature.

Lane T, Gillmore JD, Wechalekar AD, et al.

Clinical and experimental rheumatology 2015; (33(6 Suppl 94)):S46-53.

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience.

Sanchorawala V, Sun F, Quillen K, et al.

Blood 2015; (126(20)):2345-7 doi:10.1182/blood-2015-08-662726.

Secondary amyloidosis in autoinflammatory diseases and the role of inflammation in renal damage.

Scarpioni R, Ricardi M, Albertazzi V

World journal of nephrology 2016; (5(1)):66-75 doi:10.5527/wjn.v5.i1.66.

Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.

Gillmore JD, Maurer MS, Falk RH, et al.

Circulation 2016; (133(24)):2404-12 doi:10.1161/CIRCULATIONAHA.116.021612.

Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis.

Merlini G, Lousada I, Ando Y, et al.

Leukemia 2016; (30(10)):1979-1986 doi:10.1038/leu.2016.191.

Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis.

Castano A, Haq M, Narotsky DL, et al.

JAMA cardiology 2016; (1(8)):880-889 doi:10.1001/jamacardio.2016.2839.

Implementation and evaluation of amyloidosis subtyping by laser-capture microdissection and tandem mass spectrometry.

Mollee P, Boros S, Loo D, et al.

Clinical proteomics 2016; (13()):30 doi:10.1186/s12014-016-9133-x.

Amyloid A Amyloidosis.

Gaffney PM

Veterinary pathology 2017; (54(1)):5-8 doi:10.1177/0300985816677150.

18F-Sodium Fluoride PET/MR for the Assessment of Cardiac Amyloidosis.

Trivieri MG, Dweck MR, Abgral R, et al.

Journal of the American College of Cardiology 2016; (68(24)):2712-2714 doi:10.1016/j.jacc.2016.09.953.

Amyloid heart disease: genetics translated into disease-modifying therapy.

Sperry BW, Tang WHW

Heart (British Cardiac Society) 2017; (103(11)):812-817 doi:10.1136/heartjnl-2016-309914.

Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.

Hegenbart U, Bochtler T, Benner A, et al.

Haematologica 2017; (102(8)):1424-1431 doi:10.3324/haematol.2016.163246.

Analysis of the TTR gene in the investigation of amyloidosis: A 25-year single UK center experience.

Rowczenio D, Quarta CC, Fontana M, et al.

Human mutation 2019; (40(1)):90-96 doi:10.1002/humu.23669.

Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis.

Kristen AV, Ajroud-Driss S, Conceição I, et al.

Neurodegenerative disease management 2019; (9(1)):5-23 doi:10.2217/nmt-2018-0033.

Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis.

Gutiérrez-García G, Cibeira MT, Rovira M, et al.

Bone marrow transplantation 2019; (54(8)):1295-1303 doi:10.1038/s41409-019-0447-y.

De novo leukocyte chemotactic factor 2 amyloidosis in a pediatric renal allograft, 15 years post-transplant.

Shamir ER, Lee MM, Walavalkar V

Pediatric transplantation 2019; (23(3)):e13371 doi:10.1111/petr.13371.

Mass Spectrometry Amyloid Typing Is Reproducible across Multiple Organ Sites.

Holub D, Flodrova P, Pika T, et al.

BioMed research international 2019; (2019()):3689091 doi:10.1155/2019/3689091.

Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease.

Adams D, Koike H, Slama M, Coelho T

Nature reviews. Neurology 2019; (15(7)):387-404 doi:10.1038/s41582-019-0210-4.

Familial Amyloid Polyneuropathy.

Çakar A, Durmuş-Tekçe H, Parman Y

Noro psikiyatri arsivi 2019; (56(2)):150-156 doi:10.29399/npa.23502.

Myocardial Amyloidosis: The Exemplar Interstitial Disease.

Fontana M, Ćorović A, Scully P, Moon JC

JACC. Cardiovascular imaging 2019; (12(11 Pt 2)):2345-2356 doi:10.1016/j.jcmg.2019.06.023.

New developments in diagnosis, risk assessment and management in systemic amyloidosis.

Vaxman I, Dispenzieri A, Muchtar E, Gertz M

Blood reviews 2020; (40()):100636 doi:10.1016/j.blre.2019.100636.

Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.

Park J, Egolum U, Parker S, et al.

The Annals of pharmacotherapy 2020; (54(5)):470-477 doi:10.1177/1060028019888489.

Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies.

Milandri A, Farioli A, Gagliardi C, et al.

European journal of heart failure 2020; (22(3)):507-515 doi:10.1002/ejhf.1742.

Renal leukocyte chemotactic factor 2 (ALECT2)-associated amyloidosis in Chinese patients.

Li DY, Liu D, Wang SX, et al.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2020; (27(2)):134-141 doi:10.1080/13506129.2020.1722097.

Supportive Care in AL Amyloidosis.

Cibeira MT, Ortiz-Pérez JT, Quintana LF, et al.

Acta haematologica 2020; (143(4)):335-342 doi:10.1159/000506760.

Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment.

Gertz MA

American journal of hematology 2020; (95(7)):848-860 doi:10.1002/ajh.25819.

Cardiac Care of Patients with Cardiac Amyloidosis.

Itzhaki Ben Zadok O, Kornowski R

Acta haematologica 2020; (143(4)):343-351 doi:10.1159/000506919.

Effectiveness of tocilizumab in Behcet's disease: A systematic literature review.

Akiyama M, Kaneko Y, Takeuchi T

Seminars in arthritis and rheumatism 2020; (50(4)):797-804 doi:10.1016/j.semarthrit.2020.05.017.

Confirming the Diagnosis of Amyloidosis.

Wisniowski B, Wechalekar A

Acta haematologica 2020; (143(4)):312-321 doi:10.1159/000508022.

Transthyretin amyloidosis: Testing strategies and model for center of excellence support.

Nakov R, Sarafov S, Gospodinova M, et al.

Clinica chimica acta; international journal of clinical chemistry 2020; (509()):228-234 doi:10.1016/j.cca.2020.06.029.

Gateway and journey of patients with cardiac amyloidosis.

Dang D, Fournier P, Cariou E, et al.

ESC heart failure 2020; (7(5)):2418-2430 doi:10.1002/ehf2.12793.

A pharmacist's review of the treatment of systemic light chain amyloidosis.

Hughes DM, Staron A, Sanchorawala V

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2021; (27(1)):187-198 doi:10.1177/1078155220963534.

Supportive Care for Patients with Systemic Light Chain Amyloidosis.

Wong SW, Fogaren T

Hematology/oncology clinics of North America 2020; (34(6)):1177-1191 doi:10.1016/j.hoc.2020.08.007.

Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate: A Test in Evolution.

Poterucha TJ, Elias P, Bokhari S, et al.

JACC. Cardiovascular imaging 2021; (14(6)):1221-1231 doi:10.1016/j.jcmg.2020.08.027.

Early changes of nerve integrity in preclinical carriers of hereditary transthyretin Ala117Ser amyloidosis with polyneuropathy.

Chiang MC, Yeh TY, Sung JY, et al.

European journal of neurology 2021; (28(3)):982-991 doi:10.1111/ene.14698.

Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis.

Bistola V, Parissis J, Foukarakis E, et al.

Heart failure reviews 2021; (26(4)):861-879 doi:10.1007/s10741-020-10062-w.

Tafamidis: A Review in Transthyretin Amyloid Cardiomyopathy.

Lamb YN

American journal of cardiovascular drugs : drugs, devices, and other interventions 2021; (21(1)):113-121 doi:10.1007/s40256-020-00461-7.

Use of biomarkers to diagnose and manage cardiac amyloidosis.

Castiglione V, Franzini M, Aimo A, et al.

European journal of heart failure 2021; (23(2)):217-230 doi:10.1002/ejhf.2113.

Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness.

Nativi-Nicolau JN, Karam C, Khella S, Maurer MS

Heart failure reviews 2022; (27(3)):785-793 doi:10.1007/s10741-021-10080-2.

Tenosynovial complications identify TTR cardiac amyloidosis among patients with hypertrophic cardiomyopathy phenotype.

Cappelli F, Zampieri M, Fumagalli C, et al.

Journal of internal medicine 2021; (289(6)):831-839 doi:10.1111/joim.13200.

Case report regarding the evolution of electrocardiographic and echocardiographic features in cardiac amyloidosis.

Vervaat FE, Bouwmeester S, Vlaar PJ

European heart journal. Case reports 2021; (5(1)):ytaa426 doi:10.1093/ehjcr/ytaa426.

Updates in Cardiac Amyloidosis Diagnosis and Treatment.

Stern LK, Kittleson MM

Current oncology reports 2021; (23(4)):47 doi:10.1007/s11912-021-01028-8.

Drug Discovery and Development in Rare Diseases: Taking a Closer Look at the Tafamidis Story.

Burton A, Castaño A, Bruno M, et al.

Drug design, development and therapy 2021; (15()):1225-1243 doi:10.2147/DDDT.S289772.

Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis.

Palladini G, Milani P, Malavasi F, Merlini G

Cells 2021; (10(3)) doi:10.3390/cells10030545.

Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021.

Hasib Sidiqi M, Gertz MA

Blood cancer journal 2021; (11(5)):90 doi:10.1038/s41408-021-00483-7.

Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update.

Muchtar E, Dispenzieri A, Gertz MA, et al.

Mayo Clinic proceedings 2021; (96(6)):1546-1577 doi:10.1016/j.mayocp.2021.03.012.

Multidisciplinary Approaches for Transthyretin Amyloidosis.

Koike H, Okumura T, Murohara T, Katsuno M

Cardiology and therapy 2021; (10(2)):289-311 doi:10.1007/s40119-021-00222-w.

Cardiac Amyloidosis: Multimodal Imaging of Disease Activity and Response to Treatment.

Patel RK, Fontana M, Ruberg FL

Circulation. Cardiovascular imaging 2021; (14(6)):e009025 doi:10.1161/CIRCIMAGING.121.009025.

Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019.

Hester LL, Gifkins DM, M Bellew K, et al.

European journal of haematology 2021; (107(4)):428-435 doi:10.1111/ejh.13679.

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.

Kastritis E, Palladini G, Minnema MC, et al.

The New England journal of medicine 2021; (385(1)):46-58 doi:10.1056/NEJMoa2028631.

99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis.

Quarta CC, Zheng J, Hutt D, et al.

European heart journal. Cardiovascular Imaging 2021; (22(11)):1304-1311 doi:10.1093/ehjci/jeab095.

Cardiac Magnetic Resonance Predicting Outcomes Among Patients at Risk for Cardiac AL Amyloidosis.

Agha AM, Palaskas N, Patel AR, et al.

Frontiers in cardiovascular medicine 2021; (8()):626414 doi:10.3389/fcvm.2021.626414.

Amyloidosis: Multisystem Spectrum of Disease with Pathologic Correlation.

Sugi MD, Kawashima A, Salomao MA, et al.

Radiographics : a review publication of the Radiological Society of North America, Inc 2021; (41(5)):1454-1474 doi:10.1148/rg.2021210006.

Yield of bone scintigraphy screening for transthyretin-related cardiac amyloidosis in different conditions: Methodological issues and clinical implications.

Tini G, Sessarego E, Benenati S, et al.

European journal of clinical investigation 2021; (51(12)):e13665 doi:10.1111/eci.13665.

Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease.

Kastritis E, Rousakis P, Kostopoulos IV, et al.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2021; (28(4)):259-266 doi:10.1080/13506129.2021.1971192.

Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology.

Skrahina V, Grittner U, Beetz C, et al.

Annals of medicine 2021; (53(1)):1787-1796 doi:10.1080/07853890.2021.1988696.

History of extracardiac/cardiac events in cardiac amyloidosis: prevalence and time from initial onset to diagnosis.

Kharoubi M, Bézard M, Galat A, et al.

ESC heart failure 2021; (8(6)):5501-5512 doi:10.1002/ehf2.13652.

Diagnostic Work-Up of Cardiac Amyloidosis Using Cardiovascular Imaging: Current Standards and Practical Algorithms.

Korosoglou G, Giusca S, André F, et al.

Vascular health and risk management 2021; (17()):661-673 doi:10.2147/VHRM.S295376.

AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies: JACC: CardioOncology State-of-the-Art Review.

Bianchi G, Zhang Y, Comenzo RL

JACC. CardioOncology 2021; (3(4)):467-487 doi:10.1016/j.jaccao.2021.09.003.

LECT-2 amyloidosis: what do we know?

Mann BK, Bhandohal JS, Cobos E, et al.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2022; (70(2)):348-353 doi:10.1136/jim-2021-002149.

Amyloid Cardiopathy and Aortic Stenosis.

Gherasim L

Maedica 2021; (16(3)):473-481 doi:10.26574/maedica.2020.16.3.473.

Neuromuscular Complications of Systemic Amyloidosis.

Namiranian D, Geisler S

The American journal of medicine 2022; (135 Suppl 1()):S13-S19 doi:10.1016/j.amjmed.2022.01.006.

Amyloidosis from the patient perspective: the French daily impact of amyloidosis study.

Damy T, Adams D, Bridoux F, et al.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2022; (29(3)):165-174 doi:10.1080/13506129.2022.2035354.

Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment.

Gertz MA

American journal of hematology 2022; (97(6)):818-829 doi:10.1002/ajh.26569.

The clinical features and outcomes of systemic light chain amyloidosis with hepatic involvement.

Zhao L, Ren G, Guo J, et al.

Annals of medicine 2022; (54(1)):1226-1232 doi:10.1080/07853890.2022.2069281.

Utility and pitfalls of the electrocardiogram in the evaluation of cardiac amyloidosis.

Ng PLF, Lim YC, Evangelista LKM, et al.

Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc 2022; (27(4)):e12967 doi:10.1111/anec.12967.

Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study.

Gustine JN, Staron A, Szalat RE, et al.

American journal of hematology 2022; (97(9)):1189-1199 doi:10.1002/ajh.26641.

The Clinical Characteristics and Prognosis of Chinese Patients with Light-Chain Amyloidosis: A Retrospective Multicenter Analysis.

He D, Guan F, Hu M, et al.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2022; (38(3)):444-453 doi:10.1007/s12288-021-01469-y.

Concurrence of leukocyte chemotactic factor 2-associated amyloidosis and autoimmune diseases: A case report.

Wang S, Yu XJ, Li DY, et al.

Frontiers in immunology 2022; (13()):966591 doi:10.3389/fimmu.2022.966591.

Amyloidosis of the Heart and Kidney.

Adrogue HE

Methodist DeBakey cardiovascular journal 2022; (18(4)):27-33 doi:10.14797/mdcvj.1150.

Transthyretin Cardiac Amyloidosis: An Evolution in Diagnosis and Management of an "Old" Disease.

Smiley DA, Rodriguez CM, Maurer MS

Cardiology clinics 2022; (40(4)):541-558 doi:10.1016/j.ccl.2022.06.008.

Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment.

Martinez-Naharro A, Patel R, Kotecha T, et al.

European heart journal 2022; (43(45)):4722-4735 doi:10.1093/eurheartj/ehac363.

Untangling Amyloidosis: Recent Advances in Cardiac Amyloidosis.

Kim D, Choi JO, Kim K, et al.

International journal of heart failure 2020; (2(4)):231-239 doi:10.36628/ijhf.2020.0016.

Care of Patients With Transthyretin Amyloidosis: the Roles of Nutrition, Supplements, Exercise, and Mental Health.

Dasgupta NR

The American journal of cardiology 2022; (185 Suppl 1()):S35-S42 doi:10.1016/j.amjcard.2022.10.053.

Transthyretin Cardiac Amyloidosis: A Cardio-Orthopedic Disease.

Perfetto F, Zampieri M, Bandini G, et al.

Biomedicines 2022; (10(12)) doi:10.3390/biomedicines10123226.

Evaluation of laboratory diagnostic tests for light-chain clonality and bone marrow findings in AL amyloidosis.

Lee T, Park CJ, Kim M, et al.

Blood research 2023; (58(1)):71-76 doi:10.5045/br.2023.2022232.

Amyloidosis: a case series and review of the literature.

Senecal JB, Abou-Akl R, Allevato P, et al.

Journal of medical case reports 2023; (17(1)):184 doi:10.1186/s13256-023-03886-1.

AA amyloidosis of unknown aetiology: response to treatment with interleukin-1 inhibitors.

İlgen U, Uçar İ, Kılıç G, Küçükşahin O

Clinical kidney journal 2023; (16(6)):1038-1042 doi:10.1093/ckj/sfad005.

The Rise of Cardiac Amyloidosis Imaging.

Satyavolu B, Deitz J, Soman P

Journal of nuclear medicine technology 2023; (51(2)):129-132 doi:10.2967/jnmt.123.265635.

The Clinical Features and Outcomes of Renal Amyloidosis in Tunisia.

Ayed A, Salem MB, Letaief A, et al.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 2022; (33(3)):432-439 doi:10.4103/1319-2442.385967.

Detailed clinical, physiological and pathological phenotyping can impact access to disease-modifying treatments in ATTR carriers.

Beauvais D, Labeyrie C, Cauquil C, et al.

Journal of neurology, neurosurgery, and psychiatry 2024; (95(6)):489-499 doi:10.1136/jnnp-2023-332180.

Clinical, Endoscopic, and Histopathologic Observations in Gastrointestinal Amyloidosis.

Krauß LU, Schmid S, Mester P, et al.

Journal of gastrointestinal and liver diseases : JGLD 2023; (32(4)):497-506 doi:10.15403/jgld-5107.

Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study.

Jaccard A, Bridoux F, Roeloffzen W, et al.

Clinical lymphoma, myeloma & leukemia 2024; (24(5)):e205-e216 doi:10.1016/j.clml.2024.01.013.

Associations of Patients with Pericardial Effusion Secondary to Light-Chain or Transthyretin Amyloidosis- A Systematic Review.

Javed N, Singh K, Shirah J, Vittorio TJ

Current cardiology reviews 2024; (20(4)):e080324227805 doi:10.2174/011573403X280737240221060630.

Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis.

Berends M, Brunger AF, Bijzet J, et al.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2024; (31(2)):132-141 doi:10.1080/13506129.2024.2327342.

Cardiac Troponin in Patients With Light Chain and Transthyretin Cardiac Amyloidosis: JACC: CardioOncology State-of-the-Art Review.

De Michieli L, Cipriani A, Iliceto S, et al.

JACC. CardioOncology 2024; (6(1)):1-15 doi:10.1016/j.jaccao.2023.12.006.

Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy.

Streicher N, Amass L, Wang R, et al.

Cardiology and therapy 2024; (13(2)):359-368 doi:10.1007/s40119-024-00362-9.

Cardiovascular autonomic failure in hereditary transthyretin amyloidosis and TTR carriers is an early and progressive disease marker.

Chiaro G, Stancanelli C, Koay S, et al.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society 2024; (34(3)):341-352 doi:10.1007/s10286-024-01038-z.

Native State Stabilization of Amyloidogenic Proteins by Kinetic Stabilizers: Inhibition of Protein Aggregation and Clinical Relevance.

Priyanka , Raymandal B, Mondal S

ChemMedChem 2024; (19(19)):e202400244 doi:10.1002/cmdc.202400244.

Kidney Amyloidosis: Updates on Pathogenesis and Therapeutic Frontiers.

Cervantes CE, Atta MG

American journal of nephrology 2026; (57(2)):249-260 doi:10.1159/000539596.

AL amyloidosis: Singapore Myeloma Study Group consensus guidelines on diagnosis, treatment and management.

Tan M, Chen Y, Ooi M, et al.

Annals of the Academy of Medicine, Singapore 2023; (52(11)):601-624 doi:10.47102/annals-acadmedsg.2023101.

Tafamidis therapy in transthyretin amyloid cardiomyopathy: a narrative review from clinical trials and real-world evidence.

Ogieuhi IJ, Ugiomoh OM, Muzofa K, et al.

The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology 2024; (76(1)):90 doi:10.1186/s43044-024-00517-y.

Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy.

Fontana M, Berk JL, Gillmore JD, et al.

The New England journal of medicine 2025; (392(1)):33-44 doi:10.1056/NEJMoa2409134.

Treatment Approach for Advanced Systemic Light Chain Amyloidosis: A Case Report.

Hachem MAM, Nasreddine GM, Farhat S, et al.

Cureus 2024; (16(8)):e65960 doi:10.7759/cureus.65960.

Diagnosing AL and ATTR Amyloid Cardiomyopathy: A Multidisciplinary Approach.

Aus dem Siepen F, Hansen T

Journal of clinical medicine 2024; (13(19)) doi:10.3390/jcm13195873.

Secondary Amyloidosis Treated with Tocilizumab as a Complication of Temporal Arteritis.

Kudsi M, Haidar G, Abouharb D, Abouharb L

European journal of case reports in internal medicine 2024; (11(11)):004895 doi:10.12890/2024_004895.

Systemic Amyloid Light Chain Amyloidosis With Repeated Syncope Due to Severe Orthostatic Hypotension Caused by Autonomic Neuropathy: A Case Report.

Mori Y, Kenzaka T

Cureus 2024; (16(11)):e73320 doi:10.7759/cureus.73320.

Primary systemic amyloidosis: A brief overview.

Hughes MS, Lentzsch S

Presse medicale (Paris, France : 1983) 2025; (54(1)):104267 doi:10.1016/j.lpm.2024.104267.

Patient Journey to Transthyretin Cardiac Amyloidosis Diagnosis　- A Japanese Claims Database Study.

Minamisawa M, Konishi H, Kitano Y, et al.

Circulation journal : official journal of the Japanese Circulation Society 2025; (89(4)):432-441 doi:10.1253/circj.CJ-24-0666.

Supportive care for systemic amyloidosis: International Society of Amyloidosis (ISA) expert panel guidelines.

Muchtar E, Grogan M, Aus dem Siepen F, et al.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2025; (32(2)):93-116 doi:10.1080/13506129.2025.2463678.

Advances and challenges in echocardiographic diagnosis and management of cardiac amyloidosis.

Tian Y, Liu H

The international journal of cardiovascular imaging 2025; (41(6)):1021-1037 doi:10.1007/s10554-025-03362-5.

Sudoscan in ATTRv Amyloidosis: A Potential Marker of Disease Progression?

Romano A, Guglielmino V, Vitali F, et al.

Neurology and therapy 2025; (14(3)):787-800 doi:10.1007/s40120-025-00721-1.

Immunoglobulin heavy/light chain assay in the diagnosis, monitoring and follow-up of renal AL amyloidosis patients at different disease stages.

Wang Y, Liu F, Liu Y, et al.

Annals of hematology 2025; (104(4)):2287-2295 doi:10.1007/s00277-025-06345-7.

High-Sensitivity Cardiac Troponin I for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy.

De Michieli L, Sinigiani G, Guida G, et al.

Circulation. Heart failure 2025; (18(8)):e012816 doi:10.1161/CIRCHEARTFAILURE.125.012816.

NT-proBNP changes predict outcomes in elderly type 2 myocardial infarction patients.

Ma J, Li A, Bian S

BMC geriatrics 2025; (25(1)):535 doi:10.1186/s12877-025-06169-0.

Realizing the therapeutic potential of rapid knockdown of transthyretin via RNA interference in transthyretin amyloidosis.

Grogan M, Sheikh FH, Sperry BW, et al.

Molecular therapy. Nucleic acids 2025; (36(3)):102590 doi:10.1016/j.omtn.2025.102590.

A comprehensive panel of testing for amyloidosis.

Tang H, Zhao F, Zhu Y, et al.

Journal of histotechnology 2025; (48(4)):191-199 doi:10.1080/01478885.2025.2553926.

Diet-related poor nutritional status as a major challenge in the treatment of patients with amyloidosis: A systematic review.

Korovesi AAK, Pateli A, Kastritis E, et al.

Nutrition (Burbank, Los Angeles County, Calif.) 2026; (141()):112930 doi:10.1016/j.nut.2025.112930.

Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association.

Garcia-Pavia P, Gonzalez-Lopez E, Anderson LJ, et al.

European heart journal 2026; (47(1)):22-36 doi:10.1093/eurheartj/ehaf710.

Amyloidosis for the Gastroenterologist: A Comprehensive Systematic Review of Diagnosis and Management of Gastrointestinal Manifestations.

Tang MJ, Tay TY, Gibbs S, Niewiadomski O

Journal of gastroenterology and hepatology 2025; (40(12)):2842-2856 doi:10.1111/jgh.70083.

Bio-Adrenomedullin Predicts Death and Major Adverse Cardiovascular Events in Cardiac Amyloidosis: A Cross-Continental Multicenter Study.

Müller ML, Knebel F, Hahn K, et al.

Journal of the American Heart Association 2026; (15(1)):e043736 doi:10.1161/JAHA.125.043736.

Screening for Transthyretin Amyloid Cardiomyopathy in Patients With Musculoskeletal symptoms: Red Flags in the Rheumatology/Orthopedics Practice Setting.

Bardin T, Bigorre N, Hachulla E, et al.

Joint bone spine 2025; 106028 doi:10.1016/j.jbspin.2025.106028.

Multimodality Imaging in Cardiac Amyloidosis.

Chaudhari M, Ashwath ML

Journal of clinical medicine 2025; (15(1)) doi:10.3390/jcm15010163.

A Spatial Proteomics Approach to Isolate and Analyze Amyloid Proteins Using Laser Capture Microdissection and Mass Spectrometry.

Aguilan J, Horton M, Pessin JE, Sidoli S

Methods in molecular biology (Clifton, N.J.) 2026; (3015()):121-134 doi:10.1007/978-1-0716-5154-4_10.